Real-world Outcomes of Benralizumab in EGPA: A 24-Patient Series from a Severe Asthma Clinic in North India
Main Article Content
Abstract
Introduction: Eosinophilic granulomatosis with polyangiitis (EGPA) is a small- medium vessel vasculitis that has multisystem involvement. It is mostly seen in severe bronchial asthma patients. Eosinophils play a major pathological role in both the diseases. Targeted monoclonal antibodies have been emerging as a pivotal part of treatment.
Aim: To study the clinical, radiological profile of patients of Eosinophilic granulomatosis with Polyangiitis (EGPA) and the response to treatment.
Methods: A prospective study conducted in 24 confirmed EGPA patients at a tertiary care center in India. Clinical features, radiological patterns, laboratory markers, lung function parameters, and symptom scores were recorded at baseline and after 3 months of Benralizumab therapy.
Results: The mean age of cohort was 57.7 ± 14.4 years, with females 54.2%. Asthma was present in 83.3% patients. 83.3% showed AEC >150 while P-ANCA was positive in 41.7% cases. Ground-glass opacities were the most common hrct chest finding (54.2%). Sinonasal disease occurred in 71%, skin involvement in 50%, and neuropathy in 20.8% cases. After 3 months of Benralizumab, significant improvements were observed across clinical and biomarker domains. Mean AEC decreased from 671 to 288 cells/µL (p < 0.001), and mean total IgE declined from 1193 to 558 kU/L (p < 0.001). FEV₁% predicted improved from 55% to 71% (p < 0.001). Number of patients with FeNO level <25 ppb increased from 41.7% to 83.3% (p <0.002). The mean ACT improved from 15 to 20 (p <0.001), indicating better symptomatic control.
Conclusion: Patients with EGPA demonstrated characteristic clinical and radiological patterns, with early diagnosis enabled by 2022 EULAR criteria. Benralizumab produced significant improvements in eosinophilia, lung function, and symptom control within 3 months, supporting its role as an effective targeted therapy. Early recognition and biologic intervention may help prevent long-term organ damage and improve patient outcomes.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Raffray L, Guillevin L. Updates for the treatment of EGPA. Presse Med. 2020;49(3):104036.
3. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68(3):310-317.
4. Jakes RW, Kwon N, Nordstrom B, et al. Burden of illness associated with eosinophilic granulomatosis with polyangiitis: a systematic literature review and meta-analysis. Clin Rheumatol. 2021;40(12):4829-4836.
5. Berti A, Atzeni F, Dagna L, et al. Targeting the interleukin-5 pathway in EGPA: evidence, uncertainties, and opportunities. Ann Rheum Dis. 2023;82(2):164-168.
6. Koike H, Nishi R, Yagi S, et al. A review of anti-IL-5 therapies for eosinophilic granulomatosis with polyangiitis. Adv Ther. 2023;40(1):25-40.
7. Matucci A, Vivarelli E, Perlato M, et al. EGPA phenotyping: not only ANCA, but also eosinophils. Biomedicines. 2023;11(3):776.
8. Pelaia C, Calabrese C, Vatrella A, et al. Benralizumab: from the basic mechanism of action to the potential use in the biological therapy of severe eosinophilic asthma. BioMed Res Int. 2018; 2018:4839230.
9. Davanzo F, Iorio L, Codirenzi M, et al. Long-term effectiveness and safety of benralizumab in EGPA: a 3-year single-center experience. Ann Med. 2025; 57(1):2581812.
10. Comarmond C, Pagnoux C, Khellaf M, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term follow-up of 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum. 2013;65(1):270-281.
11. Emmi G, Bettiol A, Gelain E, et al. Evidence-based guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis. Nat Rev Rheumatol. 2023;19(6):378-393.
12. Doubelt I, Cuthbertson D, Carette S, et al. Clinical manifestations and long-term outcomes of eosinophilic granulomatosis with polyangiitis in North America. ACR Open Rheumatol. 2021; 3(6):404-412.
13. Sada KE, Amano K, Uehara R, et al. A nationwide survey on the epidemiology and clinical features of eosinophilic granulomatosis with polyangiitis (Churg–Strauss) in Japan. Mod Rheumatol. 2014;24(4):640-644.
14. Nanzer AM, Dhariwal J, Kavanagh J, et al. Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis. ERJ Open Res. 2020;6(4):00165-2020.
15. Grayson PC, Ponte C, Suppiah R, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis. Arthritis Rheumatol. 2022;74(3):386-392.
16. Trivioli G, Terrier B, Vaglio A. Eosinophilic granulomatosis with polyangiitis: understanding the disease and its management. Rheumatology (Oxford). 2020;59(Suppl 3):iii84-iii94.
17. Kim YK, Lee KS, Chung MP, et al. Pulmonary involvement in Churg-Strauss syndrome: analysis of CT, clinical, and pathologic findings. Eur Radiol. 2007;17(12):3157-3165.
18. Cottin V, Bel E, Bottero P, et al. Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Eur Respir J. 2016;48 (5):1429-1441.
19. Marques CC, Fernandes EL, Miquelin GM, Colferai MM. Cutaneous manifestations of Churg-Strauss syndrome: key to diagnosis. An Bras Dermatol. 2017;92(1):56-58.
20. White JP, Dubey S. Eosinophilic granulomatosis with polyangiitis: a review. Autoimmun Rev. 2023; 22(1):103219.
21. Fagni F, Bello F, Emmi G. Eosinophilic granulomatosis with polyangiitis: dissecting the pathophysiology. Front Med (Lausanne). 2021;8:627776.
22. Carlson JA. The histological assessment of cutaneous vasculitis. Histopathology. 2010;56(1):3-23.
23. Tabb ES, Duncan LM, Nazarian RM. Eosinophilic granulomatosis with polyangiitis: cutaneous clinical and histopathologic differential diagnosis. J Cutan Pathol. 2021;48(11):1379-1386.
24. Rowell J, et al. Measuring the humanistic burden of EGPA: a systematic review. Ann Rheum Dis. 2024;83:1958-1959.
25. Spataro F, Solimando AG, Di Girolamo A, et al. Efficacy and safety of benralizumab in eosinophilic granulomatosis with polyangiitis: a meta-analysis of eight studies. Eur J Clin Invest. 2025;55(2):e14333.
26. Guntur VP, Manka LA, Denson JL, et al. Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol Pract. 2021;9(3):1186-1193.
27. Nanzer AM, Maynard-Paquette AC, Alam V, et al. Long-term effectiveness of benralizumab in eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol Pract. 2024;12(3):724-732.
28. Martínez-Rivera C, Garcia-Olivé I, Urrutia-Royo B, et al. Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis. BMC Pulm Med. 2021;21(1):35.
29. Laviolette M, Gossage DL, Gauvreau G, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013;132(5):1086-1094.
30. Jackson DJ, Wechsler ME, Bleecker ER, et al. Systematic literature review of real-world outcomes of benralizumab in eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol Pract. 2025;13(11):3054-3065.e4.
31. Padoan R, et al. Benralizumab as a glucocorticoid-sparing treatment option for severe asthma in eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol Pract. 2020;8(9):3225-3227.e2.